Shares of Boston-based Zafgen plunged more than 32 percent in pre-market trading after the company announced the U.S. Food and Drug Administration (FDA) has slapped a clinical hold on its plans to launch a clinical trial in the United States for an experimental diabetes medicine due to safety concerns.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,